| Autor: |
Mustafa Merter, Mehmet Hilmi Dogu, Mehmet Ali Erkurt, Ahmet Sarici, Abdulkadir Basturk, Sinan Demircioğlu, Turgay Ulas, Serdal Korkmaz, Düzgün Özatlı, Buğra Sağlam, Metin Bagci, Fevzi Altuntaş, Tuba Hacibekiroglu, Jale Yıldız, Emine Gültürk, Fehmi Hindilerden, Bülent Eser, Mehmet Sinan Dal, Sinem Namdaroglu, Omer Ekinci |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Journal of Pharmaceutical Research International. :92-98 |
| ISSN: |
2456-9119 |
| DOI: |
10.9734/jpri/2020/v32i4131047 |
| Popis: |
Objective: Pomalidomide is a new generation thalidomide analogue. Effectiveness as a single agent or combination with low dose dexamethasone has been in the treatment of relapse/refractory Multiple Myeloma (MM). The aim of the present study was to share the experience of different oncology centres with pomalidomide treatment in patients with relapsed/refractory MM. Materials and Methods: Seventy-three patients from 16 centres were enrolled into the study. The patients were followed for a median of 6 months. Relapsed/refractory MM patients who received at least one line of treatment before pomalidomide were included into the study. ISS, R-ISS and Eastern Cooperative Oncology Group (ECOG) scores of the patients and treatment-related side effects were evaluated. Results: As a result of the median follow-up for 6 months, 36% (26/72) of the patients presented progression. The estimated median PFS was found 29 months. The Cox regression analysis revealed that ECOG affected PFS only, myeloma subtype; ISS and R-ISS scores did not affect PFS. The most common side effects with pomalidomide treatment in our population include neutropenia, infections, anaemia and thrombocytopenia. Conclusion: In our study, it was statistically shown that the ECOG score was effective in survival in relapsed / refractory MM patients treated by pomalidomide. Therefore, we recommend evaluation of the ECOG score for each patient before treatment in eligible cases. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
